Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Aug 23;120(8):1597-600.
doi: 10.1182/blood-2012-04-421883. Epub 2012 Jun 6.

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

Saad Z Usmani  1 , Rachel Sexton, Antje Hoering, Christoph J Heuck, Bijay Nair, Sarah Waheed, Yazan Al Sayed, Nabeel Chauhan, Nisar Ahmad, Shebli Atrash, Nathan Petty, Frits van Rhee, John Crowley, Bart Barlogie
Affiliations
Randomized Controlled Trial

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

Saad Z Usmani et al. Blood. .

Abstract

Thalidomide and lenalidomide constitute an important part of effective myeloma therapy. Recent data from the Intergroup Francophone du Myélome, Cancer and Leukemia Group B, and Gruppo Italiano Malattie Ematologiche dell Adulto MM-015 trials suggest that lenalidomide maintenance therapy is associated with a higher incidence of second primary malignancies (SPMs), including both hematologic and solid malignancies. In the present study, we analyzed data from the Total Therapy 2 (TT2) trial, along with the 2 Total Therapy 3 (TT3) trials. TT2 patients were assigned randomly to either a control group (no thalidomide) or to the experimental group (thalidomide during induction, between transplantations, and during consolidation and maintenance). The 2 TT3 trials used thalidomide and bortezomib during induction, before and in consolidation after tandem melphalan-based transplantation; TT3A applied VTD (bortezomib, thalidomide, dexamethasone) in the first year of maintenance and TD for 2 more years, whereas TT3B used VRD (bortezomib, lenalidomide, dexamethasone) maintenance for 3 years. The cumulative incidence of SPMs did not differ significantly among the TT trial components when measured from enrollment (P = .78) or from initiation of maintenance (P = .82). However, a pairwise comparison of the TT2 arms suggested a lower incidence of hematologic SPMs in the thalidomide maintenance arm (hazard ratio = 0.38; P = .09). These trials are registered at www.clinicaltrials.gov as NCT00573391 (TT2), NCT00081939 (TT3A), and NCT00572169 (TT3B).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Timing of onset of all SPMs in TT2, TT3A, and TT3B. From enrollment (A) and from maintenance (B).
Figure 2
Figure 2
Timing of onset of solid-tissue SPMs in TT2, TT3A, and TT3B. From enrollment (A) and from maintenance (B).
Figure 3
Figure 3
Timing of onset of hematologic SPMs in TT2, TT3A, and TT3B. From enrollment (A) and from maintenance (B).
See this image and copyright information in PMC

Comment in

  • Second to none.
    Rajkumar SV. Rajkumar SV. Blood. 2012 Aug 23;120(8):1537-9. doi: 10.1182/blood-2012-07-439158. Blood. 2012. PMID: 22918420

References

    1. Kyle RA, Rajkumar SV. Multiple Myeloma. N Engl J Med. 2004;351(18):1860–73. - PubMed
    1. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108(10):3289–3294. - PubMed
    1. Abdelkefi A, Ladeb S, Torjman L, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood. 2008;111(4):1805–1810. - PubMed
    1. Palumbo A, Bringhen S, Rossi D, et al. A prospective, randomized phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients [abstract]. Blood (ASH Annual Meeting Abstracts) 2008;114:652.
    1. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759–1769. - PubMed

Publication types

MeSH terms

Associated data